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Abstract 
 
The generation of tissue resident memory (TRM) cells at the body surfaces to provide a front 
line defence against invading pathogens represents an important goal in vaccine 
development for a wide variety of pathogens. It has been widely assumed that local vaccine 
delivery to the mucosae is necessary to achieve that aim. Here we characterise a novel 
micro-needle array (MA) delivery system fabricated to deliver a live recombinant human 
adenovirus type 5 vaccine vector (AdHu5) encoding HIV-1 gag. We demonstrate rapid 
dissolution kinetics of the microneedles in skin.  Moreover, a consequence of MA vaccine 
cargo release was the generation of long-lived antigen-specific CD8+ T cells that accumulate 
in mucosal tissues, including the female genital and respiratory tract. The memory CD8+ T 
cell population maintained in the peripheral mucosal tissues was attributable to a MA 
delivered AdHu5 vaccine instructing CD8+ T cell expression of CXCR3+, CD103+, CD49a+, 
CD69+, CD127+ homing, retention and survival markers. Furthermore, memory CD8+ T cells 
generated by MA immunisation significantly expanded upon locally administered antigenic 
challenge and showed a predominant poly-functional profile producing high levels of IFNγ 
and Granzyme B. These data demonstrate that skin vaccine delivery using microneedle 
technology induces mobilization of long lived, poly-functional CD8+ T cells to peripheral 
tissues, phenotypically displaying hallmarks of residency and yields new insights into how to 
design and deliver effective vaccine candidates with properties to exert local 
immunosurveillance at the mucosal surfaces 
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1.Introduction  
 
Human immunodeficiency virus (HIV) remains a global health threat, and no HIV vaccine 
developed to date has achieved prolonged or significant protection in humans. Therefore, 
the development of a safe and effective HIV vaccine for prophylactic and therapeutic use 
represents not only an unprecedented scientific challenge but also a fundamental necessity 
to redress the economic and social impact of infection [1]. While intense efforts have been 
directed to develop vaccines that provide protective antibody responses against HIV [1], it is 
equally acknowledged that antigen-specific memory CD8+ T cells contribute a critical, 
complementary role in the control of HIV-1 infection [1-3]. It is currently understood that 
memory CD8+ T cells provide a multi-layered protective immune response, by residing in 
different anatomic niches, as lymphoid tissue-based ‘central’ memory CD8+ T-cells (TCM), as 
circulating effector memory CD8+T-cells (TEM) that patrol non-lymphoid tissues and as non-
lymphoid tissue resident memory T cells (TRM) [4-6]. Each subset express distinct phenotypic 
markers and contribute distinct roles in immuno-surveillance of the host [4-6]. As a 
consequence there is an unmet need to develop vaccine strategies that generate memory 
CD8+ T cells at each of these anatomic niches as an integrated immune surveillance 
network against mucosally acquired pathogens.  
 
 Under physiological conditions, TRM cells by virtue of their residence in epithelial barrier 
tissues at the interface between the host and the environment, such as the skin, 
gastrointestinal, respiratory and reproductive tracts can respond rapidly to pathogen 
challenge at these sites, independently of T cell recruitment from the blood [7, 8]. They thus 
mediate the rapid protective immunity that is the hallmark of adaptive immune memory [7]. 
Therefore, vaccination strategies that can in addition programme antigen experienced T 
cells to provide long term memory at the mucosal surfaces and respond rapidly to antigen 
re-encounter, would be of immense benefit in the development of effective vaccines against 
mucosally acquired pathogens, including HIV. 
 
 The skin is an attractive target for vaccine delivery for ease of administration and as a 
consequence of the high density of antigen presenting cells localized in the epidermis and 
dermis that are accessible for acquisition of vaccine antigens [9-12]. Current vaccination 
strategies involve the use of intra-dermal needle injections as a system for vaccine delivery 
to this rich network of cutaneous antigen-presenting cells. However, there are numerous 
drawbacks with this mode of vaccination including the need for trained staff, pain/bleeding 
associated with the injection itself, the requirement for safe needle disposal procedures and 
the risk of accidental injury or inappropriate needle reuse. Moreover, in resource-limited 
settings, an additional level of consideration is the need to maintain a continuous ‘cold chain’ 
for vaccine storage and transport to prevent any loss in potency. These downsides have led 
to the development of new designs for vaccine delivery such as microneedle arrays (MA), 
that are not only safe, cost-effective and thermostable, but most importantly proven to elicit 
systemic and mucosal immunity and improve vaccine efficacy [13, 14].  
 
MAs fabricated from a dissolvable polymer matrix to contain viral vector based vaccines, 
including adenovirus vectors, are at the forefront of recent technological advances that 
successfully achieve live vector thermostability with a delivery platform that exploits the rich 
antigen presenting cell network in the skin to induce potent cellular immune responses [13, 
15, 16]. We have previously reported the fabrication of MAs from sodium 
carboxymethylcellulose (Na-CMC), an FDA approved injectable bio-material, that is inert, 
non-toxic, free of mutagenic or carcinogenic properties and has been used as a GMP 
reagent in the clinic over the last 50 years [17]. By incorporating a disaccharide in the Na-
CMC MA matrix, we reported the thermal stabilisation of adenovirus vectors at ambient 
temperature, with no significant loss in immunogenicity when administered to mice as 
determined by induction of high frequency of antigen-specific CD8 T cells [13]. In vivo 
confocal microscopy of MAs delivered to CD11c eGFP reporter mice demonstrated 
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dissolution of the MA cargo following penetration of mouse skin and uptake by CD11c+ 
antigen presenting cells in the dermis [13]. Moreover, MA vaccination with live, recombinant 
adenovirus (Ad) virus vectors prime high-frequency effector CD8+ T cells that express multi-
functional cytokines, detected in systemic and mucosal associated lymphoid tissues [13, 16]. 
However, the capacity of MA vaccination to programme antigen experienced T cells to 
provide long term memory, especially at the mucosal surfaces and respond rapidly to 
antigen re-encounter which is the hallmark of a vaccine, remains largely unexplored.  
 
In this study, we demonstrate that a simple, thermostable MA, fabricated to contain a 
recombinant human adenovirus type 5 vector (rAd5Hu) encoding HIV- 1 gag, rapidly 
dissolves in skin following application and generated robust antigen-specific CD8+ T cells in 
the blood and non–lymphoid mucosal tissues, including the genital and respiratory tracts. 
Moreover, vaccine elicited CD8+ memory T cells were retained in peripheral tissues for at 
least one-year post-vaccination and critically, retained the functional capacity to respond to 
secondary antigen challenge by production of antiviral effector molecules. As the induction 
of robust TRM responses at the barrier surfaces represents an imperative goal for an effective 
HIV vaccine, this study demonstrates the promising potential of an accessible MA skin 
immunisation platform to elicit memory TRM as part of a multi-layered protective immune 
response. 
 
2. Material and Methods  
 
2.1. Recombinant adenovirus vaccine  
A recombinant E1, E3 deleted human adenovirus type 5 (AdHu5) vaccine vector encoding 
HIV-1 CN54gag (AdHu5-CN54gag) was used which has been described previously [13]. 
High titre virus stocks were prepared on AD293 cells (Cell Biolabs, Inc, San Diego, USA) 
and purified by CsCL centrifugation as previously described [18]. Viruses were tested for 
endotoxin using the Kinetic-QCL assay (Lonza, Slough, UK), according to the 
manufacturer’s instructions. 
2.2. Adenovirus titres 
 
Virus particle titre (vp) based on viral genome equivalence was determined using the Quant-
it PicoGreen dsDNA assay kit (Invitrogen). Virus samples were denatured for 30 min at 55oC 
in 0.05% sodium dodecyl sulphate (SDS, Sigma) containing Tris-EDTA (TE, Sigma). Virus 
DNA binding to fluorescent PicoGreen was measured at 485 nm excitation wavelength (λ 
ex) and 535 nm emission wavelength (λ em) using the PicoGreen FluroScannerTM with 
Ascent 2.5 software. Calculation of virus titre in particles per ml was computed from the 
extrapolated concentration multiplied by the dilution factor and particle number factor, which 
was determined as 2.5 x 10
10 
for Ad5, as described previously [18]. 
 
2.3. Fabrication of microneedle arrays (MA) 
Dissolvable microneedles (1500 µm in length, 670 µm in base diameter and 44 per array) 
were fabricated by a centrifugation casting method using an inverted cone shaped silicone 
template as described previously [13].  In brief, the needle tips were prepared from sodium 
carboxymethylcellulose (Na-CMC), a biocompatible, highly water-soluble polymer to provide 
mechanical strength and sucrose, as a protein stabilizer [13]. AdHu5-CN54gag was 
formulated in the matrix of the needle tips. Additional mechanical strength was added by 
layering a second matrix (12% Na-CMC, 4.8% lactose) to create the needle shaft and finally 
a pre-made membrane (8% Na-CMC, 0.8% lactose) applied to the needle base. 
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2.4. Immunisation of mice  
C57BL/6 (B6), 6-8 weeks old, female mice of H-2b haplotype were purchased from Envigo. 
MAs were applied manually with gentle pressure to the dorsal skin of mice, shaved of hair 
and depilated with hair removal cream (VeetTM) as described previously [13]. All animal 
husbandry and experimentation was approved under a project license granted by the United 
Kingdom Home Office.  
2.5. Isolation of cells from blood and tissues  
In some experiments, blood was collected from the tail vein into EDTA-coated Eppendorf 
tubes and further treated with red blood cell lysis buffer (Sigma–Aldrich) prior to Ab staining. 
Lungs and female genital tracts (GTs) were harvested from perfused female mice and 
broncho-alveolar lavage (BAL) fluid was also collected where indicated as described 
previously [19]. 
 
Single cell suspensions from the spleen were prepared in complete RPMI medium (RPMI 
1640) supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine 
(Invitrogen), 50 μM 2-mercaptoethanol (Invitrogen) and 10% heat inactivated FBS (Biosera). 
Erythrocytes were depleted by treatment with red blood cell lysis buffer (Sigma–Aldrich). 
Single cell suspensions from the mucosal tissues were obtained by enzymatic digestion for 
30 min at 37 °C in complete RPMI 1640 containing 1 mg/mL Collagenase D (RocheTM) and 
0.02 mg/mL DNase I from bovine pancreas (RocheTM).  
 
2.6. Antibodies and reagents for flow cytometry 
The following antibodies were purchased from BD Bio-sciences: purified anti-Fc_RII/III mAb 
(CD16/32, 2.4G2), anti-CD8 (53–6.7), anti-CD4 (RM4-5), anti-CD3 (145-2C11), anti-CD62L 
(MEL-14), anti-CD127 (SB/199), anti-KLRG-1 (2F1), anti-CD103 (2E7), anti-CD49a (HMα1), 
anti-CD69 (H1.2F3), anti-CXCR3 (CXCR3-173) and anti-CD45.2 (104). In addition, anti-IFNγ 
(XMG1.2) and anti-Granzyme B (NGZB) were obtained from eBioscience, and anti-MHCII 
(M5/114.15.2) from Biolegend. Flurophore-conjugated tetramer to the immunodominant H-
2Db restricted HIV-1 CN54 gag 308-318 epitope (Db/CN54gag) for identification of HIV-1 
CN54gag specific CD8 T cells as described previously [13] was kindly synthesized by the 
NIH Tetramer core facility (Emory University, USA).   
2.7. Cell staining for flow cytometry 
Cells were stained with the Db/CN54gag tetramer for 15 min at room temperature, followed 
by addition of cell surface antibodies (20 min) and then re-washed.  
For intracellular cytokine staining, cells were washed, counted, resuspended at 1x106/mL 
and restimulated in RPMI 10 % medium at 37°C for 4 h with 50 ng/ml phorbol myristate 
acetate (PMA, Sigma-Aldrich), 500 ng/ml Ionomycin (Sigma-Aldrich) in the presence of 
Brefeldin A (Golgi Plug, BD Biosciences). Following surface staining, cells were fixed and 
permeabilized by incubating in BD CytoFix-CytoPerm for 20 min in the dark at 4˚C. The cells 
were then washed twice with Perm/Fix wash buffer and re-suspended in 50 μl of the BD 
Perm/wash buffer (BD Pharmingen™) with fluorochrome conjugated monoclonal antibody 
and incubated for 30 min in the dark at 4˚C. Cells were then washed twice in Perm/wash 
buffer prior to flow cytometry analyses.   
Samples were acquired using a BD FACSCanto II or BD SORP Fortessa™ flow cytometers 
and analysed using FlowJo software version 9.7.5 (Tree Star). 
2.8. Vaginal antigen challenge  
150 days post MA immunisation, mice were injected subcutaneously with 3 mg of Depo-
Provera (Pfizer), a long-lasting progestin, in 100 µL of sterile PBS 5 days before intravaginal 
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challenge. Groups of mice were challenged by depositing 20 µg of HIV-1 CN54 gag308-318 
peptide (ProImmune) and 30g of CpG ODN 1826 (InvivoGen) into vaginal wall and 
monitored for 5 days.  
2.9. Statistical analysis 
Results were analysed with GraphPad PRISMTM version 6.0 (San Diego, Ca, USA). 
Comparisons between groups were performed using a one-way ANOVA in conjunction with 
Bonferroni post analyses test. Data are shown as mean ± SEM. Probability values are 
expressed as following: ***P<0.001, **P<0.01 and *P<0.05.  
 
 
3. Results 
 
3.1. Microneedle Array (MA) mediated skin delivery 
 
To evaluate the potential of a dried rAdHu5-CN54gag vaccine in a needle-free delivery 
system, dissolvable microneedles (1,500 µm in length, 44 per array) were fabricated within a 
silicone template. A Na-CMC-sucrose matrix blended with virus formed the needle tips (Fig. 
1A). Mechanical strength was added by layering a second matrix [12% (wt/vol) Na-CMC, 
4.8% (wt/vol) lactose] creating the needle shaft and applying a premade membrane [8% 
(wt/vol) Na-CMC, 0.8% lactose) to the needle base. Each MA patch in total contained an 
average of 8 × 108 virus particles (vp) of rAdHu5 CN54gag determined by virus recovery. 
The MA’s were mechanically strong and punctured the back skin of B6 mice when gentle 
pressure was applied to the MA base plate. At the same time, the MA composition facilitated 
rapid dissolution. Representative images of a MA patch prior to application and following 
removal from the skin (Fig 1B) illustrate that a reduction in needle length by approximately 
two-thirds is achieved within 3 min of application (Fig 1B). Coincident with removal of the MA 
patch, micron scale punctures within the skin corresponding to the array template were 
observed (Fig 1C). These data indicate that the MA design has the capacity to delivery a 
vaccine cargo into the skin. 
 
Fig. 1: Microneedle Array (MA) mediated skin delivery. (A) Schematic representation 
of the mechanism of action of the dissolving MA. (B) MA fabricated with rAdHu5-
CN54gag in a sucrose-Na-CMC matrix pre-(left) and post-(right) application.  (C) En 
face view of B6 back skin (left) before and (right) 3 min after MA application.  
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3.2. In vivo vaccine release profile from MA’s encapsulating rAdHu5-CN54gag 
 
We next sought to determine the kinetics of rAd5Hu vectored vaccine release in B6 mice 
following MA application to skin, because such information is germane to establishing the 
most effective and consistent delivery schedule necessary to evaluate the immunogenic 
capacity of this delivery platform in this model system. To that end, MA’s fabricated to 
contain a rAd5Hu-CN54gag vaccine were applied to dorsal skin of B6 mice over a time 
course from 0.5 to 15 min. Vaccine release was quantified as the mean difference in Ad5 
virus particle titer per MA before application to that remaining in the MA base plate after 
retrieval from the skin. The release profile was rapid; an initial release was determined within 
0.5 min and increased over 3 min of MA application in the skin. Extended application beyond 
3 min did not increase the amount of virus released from the encapsulating MA matrix (Fig 
2). Therefore, we established that a 3 min application was sufficient to optimally deliver virus 
from this MA formulation onto the dorsal skin of B6 mice. 
 
 
 
 
  
Fig. 2: In vivo vaccine release profile from microneedle arrays encapsulating a 
rAdHu5 encoding HIV-1 CN54 gag.  MAs containing a rAdHu5 vector encoding HIV-1 
CN54 gag within a water-soluble matrix were applied to murine back skin over a time 
course of 0.5 to 15 min. After application, the remaining MA base-plates were 
dissolved in PBS to release residual encapsulated virus and rAdHu5-CN54gag titre 
quantitated by PicoGreen assay as virus particle number (vp). rAdHu5-CN54gag 
delivered to the skin per single MA was calculated as the difference in MA vp number 
before and after application. Data are pooled from two independent experiments, n=6-
10 per each time point. 
 
3.3. Ag-specific CD8+ T cells are elicited by MA immunisation and express 
homing/retention markers in the female genital tract 
 
Previously we established that MA immunisation elicits primary effector T cell responses 
equipotent with conventional injectable routes of vaccine delivery [13]. As a next step, it was 
incumbent to examine the capacity of the dried rAdHu5-CN54gag MA platform to induce 
durable immune responses. Here we focused on CD8+ T cell immunity, acknowledged to be 
highly desirable in the context of HIV control [20]. Groups of B6 mice were immunized by 
rHuAd5-CN54gag MA application to the skin and antigen-specific CD8+ T-cell expansion 
tracked by tetramer to the immunodominant Db-restricted HIV-1 CN54 gag308–318 epitope 
(Db/CN54gag) in blood and genital tract tissues at day 28 post immunisation (Fig. 3A). A 
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substantial population of Db/CN54gag tetramer+ CD8+ T cells was detected in the systemic 
compartment (5-7%)  (Fig. 3B and 3C) and importantly also in the GT of immunized female 
mice (20-30%) (Fig. 3D and 3E). 
 
Fig. 3: MA delivery of a rAdHu5 vector encoding HIV-1 CN54 gag induces systemic 
and mucosal CD8+ T cell memory responses. (A) Female C57BL/6 mice were 
immunised with rAdHu5-CN54 gag virus by dried MA application to dorsal skin or left 
naïve. Blood and genital tract tissues were collected 28 days post immunisation for 
flow cytometric analysis. Frequency of Db/CN54gag tetramer expressing cells in 
blood (B) and genital tract (D) induced by MA immunisation is shown from a gated 
CD45+CD8+ population. Values (B and D) represent percentage of cells in each gate 
and are representative of four naïve and nine vaccinated mice from two independent 
experiments. (C and E); Bar graphs represent the frequency of Db/CN54gag Tetramer+ 
CD8+T cells in blood (C) and genital tract (E) of rAdHu5-CN54 gag MA immunised 
mice.  
 
As skin MA immunisation induced Ag-specific CD8+ T cells localized in mucosal non-
lymphoid tissue at day 28 after immunisation, we analyzed tetramer-specific CD8
+
 T cells in 
the blood and infiltrating the GT for markers that instruct memory CD8 T cells to home, to be 
retained and survive in non-lymphoid tissue (Fig 4A).  Db/CN54gag tetramer+ CD8+ T cells 
infiltrating the GT (Fig. 4B) showed increased expression of an early memory / homeostatic 
survival marker CD127 [21], relative to that expressed by the circulating systemic pool of 
Db/CN54gag tetramer+ CD8+ T cells. In sharp contrast, expression of killer lectin receptor G1 
(KLRG1) a marker of activated terminally differentiated cells [22] was considerably lower on 
Db/CN54gag tetramer+ CD8+ T cells infiltrating the GT (19.2%) when cross compared to 
Db/CN54gag tetramer+ CD8+ T cells isolated from the systemic circulation (72.1%; Fig. 4C). 
Likewise, Db/CN54gag tetramer+ CD8+ T cells infiltrating the GT did not express CD62L, a 
lymphoid tissue trafficking receptor (Fig. 4B and 4C). Consistent with this observation, GT 
infiltrating CD8+ T cells demonstrated a substantial increase in expression of markers 
associated with non-lymphoid tissue residency, CD49a, CD69 and CD103, representing 
78.2%, 61.2% and 72.8% of the Db/CN54gag tetramer+ CD8+ population respectably as 
compared in the blood (0.41%, 39.8% and 0% of the Db/CN54gag tetramer+ CD8+ 
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population respectably (Fig. 4D). Noticeably, the expression of CXCR3, a chemokine 
receptor that is highly expressed on effector T cells, was still co-expressed on Db/CN54gag 
tetramer+ CD8+ T cells infiltrating genital tissue on day 28 post MA immunisation, while 
downregulation of this marker was apparent on circulating Db/CN54gag tetramer+ CD8+ T 
cells (Fig. 4D). Thus MA immunisation through the skin led to the instruction and 
accumulation of a memory pool of antigen-specific CD8+ T cells in the GT delineated by 
peripheral tissue homing/retention markers (CD49a
+
, CD69
+
, CD103
+
, CXCR3
+
) consistent 
with a tissue-resident memory T cell phenotype.  
 
Fig. 4: Memory CD8+ T cells elicited by MA vaccination express peripheral tissue 
homing and retention and markers in the female genital tract. (A) Db/CN54gag 
tetramer+ CD8+ T-cells were assessed in the blood and genital tracts of female B6 
mice 28 days post immunisation with rAdHu5-CN54gag MA. (B) Dot plots of 
Db/CN54gag-specific CD8+ T cells in blood (upper panel) and genital tracts (lower 
panel) 28 days after MA immunisation with rAdHu5-CN54 gag. (C) Representative 
histograms indicating the frequency of CD8+ T cell differentiation/ memory markers 
(KLRG1, CD127 and CD62L) expressed by Db/CN54gag tetramer+ CD8+ T cells (red 
lines) isolated from blood (upper panels) or genital tracts (lower panels) of rAdHu5-
CN54 gag MA immunized mice. Grey histograms represent isotype control staining. 
(D) Representative histograms indicating the frequency of CD103, CD49a, CD69 or 
CXCR3 expressing Db/CN54gag tetramer+ CD8+ T cells (red lines) isolated from blood 
(upper panels) or genital tracts (lower panels) of rAdHu5-CN54gag MA immunized 
mice. Grey histograms represent staining with isotype controls. Data are 
representative of four naïve and nine vaccinated mice from two independent 
experiments. 
 
3.4. CD8+ T cell memory and recall responses in the genital tract after MA vaccination 
 
A fundamental requirement of vaccination is the generation of immunological memory and 
the ability to elicit CD8+ T cells that respond rapidly to antigen on secondary encounter. To 
that end, we investigated the recall capacity of Db/CN54gag tetramer+ CD8+ T cells present 
150 days after a single vaccination with a candidate rAd5Hu HIV-1 CN54 gag vaccine 
delivered by MA (Fig 5A). Over 5% of total CD8+ T cells isolated from the female GT of MA 
vaccinated mice stained for the Db/CN54gag tetramer at 150 days post vaccination (Fig. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
5B). To determine the recall capacity of MA primed CD8+ T cells, mice were boosted 
(antigen challenged) intra-vaginally at day 150 post-vaccination with a CpG adjuvanted 
peptide corresponding to the immunodominant HIV-1 CN54 gag308–318 epitope (Fig. 5A). A 
significant increase in the frequency of Db/CN54gag tetramer+ CD8+ T cells was detected in 
GT tissue on day 5 following intra-vaginal antigen boost of vaccinated mice when cross 
compared with vaccinated but non-boosted mice (p< 0.05; Fig.5C).  To determine the 
phenotype of responding Db/CN54gag tetramer
+
 CD8
+
 T cells, we selected CD62L and 
KLRG-1 to define; tissue resident effector memory cells as CD62L−KLRG-1− and effector T 
cells as CD62L−KLRG-1+ [23]. A substantial proportion of Db/CN54gag tetramer+ CD8+ T 
cells from the GT of antigen challenged female mice co-expressed high levels of KLRG-1 
(95.2%) indicative of their effector phenotype (Fig 5D) while, inversely, Db/CN54gag 
tetramer+ CD8+ T cells in the GT of MA immunised, but non-challenged mice, mostly 
retained an effector memory phenotype, lacking KLRG-1 or CD62L expression (Fig 5D). 
Therefore, rAd5Hu-CN54gag MA vaccination generates antigen-specific CD8+ T cells that 
are retained over an extended time frame at the mucosal tissues and are able to rapidly 
expand in significant number upon locally administered antigenic challenge (Fig 5D).  
 
 
 
Fig. 5: Durable CD8+ T cell memory and recall responses in the genital tract. (A) 
Schematic representation of the experimental protocol. 150 days after immunisation 
with rAdHu5-CN54 gag by MA, groups of mice were either challenged intravaginally 
with antigen (20 µg HIV-1 CN54 gag308-318 peptide and 30 µg of CpG) or with PBS. A 
control group of naïve mice received the same antigen challenge dose intravaginally. 
Five days post-antigen challenge, isolated genital tract tissue was assessed for the 
frequency of effector and memory markers expressed on Db/CN54gag tetramer
+
 cells. 
(B) Dot plots of Db/CN54gag tetramer+ cells (derived from a CD45+CD3+CD8+ gate) 
from genital tract tissue isolated from (left panel; -boost) MA only immunized mice, 
(middle panel; +boost) MA immunized and intravaginal antigen challenged mice and 
(right panel) naïve mice challenged with antigen intravaginally. (C) Bar graph 
indicates the frequency of Db/CN54gag tetramer+ CD8+ cells (mean ± SEM) of each 
group of mice. (D) Frequency of effector/memory markers (KLRG1 and CD62L) 
expressed by Db/CN54gag tetramer+ CD8+ T cells isolated from the genital tract of 
memory mice (left), or mice boosted with antigen (HIV-1 CN54 gag308-318 peptide and 
CpG (right). Data are representative of two independent experiments (n=4/group). 
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3.5. rAd5Hu-CN54gag MA immunisation generates long-lived tissue resident memory 
CD8+ T cells within female genital tract tissue 
 
To assess the persistence of immunological memory upon MA immunisation, we 
investigated the capacity of the live virus vectored MA platform to program long lived, 
antigen-specific memory cells in mice. For at least one year following rAd5Hu-CN54gag MA 
immunisation, tractable HIV-1 CN54 gag308–318 CD8
+
 T cells were detected not only in the 
systemic compartment but also in the GT of immunized female mice (Fig. 6A and 6B). The 
Db/CN54gag tetramer+ CD8+ T cells retained their effector memory phenotype, as 
characterised by CD62L- and KLRG-1- expression of cells isolated from both the systemic 
and GT compartment. In contrast, high-level co-expression of markers of tissue residency, 
CD103, CD69, CD49a and CXCR3 was restricted to GT derived Db/CN54gag tetramer+ 
CD8+ T cells (Fig. 6C, 6D and 6E). Likewise, the majority of GT resident Db/CN54gag 
tetramer+ CD8+ T cells elicited by MA vaccination expressed CD127, a marker for long-term 
survival, which was absent from their circulating counterparts (Fig 6E). Thus the bulk of 
antigen specific CD8
+
 T cells retained for up to one year in the GT tissue after MA 
vaccination are TRM, programed with a receptor dependence on CXCR3 ligands for their 
homing/ retention in GT tissue and IL-7 for tonic survival through CD127 (IL-7 receptor). 
 
Fig. 6:  rAdHu5-CN54gag MA immunisation generates long-lived, antigen-specific, 
tissue resident memory CD8+ T cells within female genital tract tissues.  (A) 
Schematic of the experimental design to assess Db/CN54gag tetramer+ CD8+ T-cells in 
blood and genital tract of female mice 365 days after MA immunisation with rAdHu5-
CN54gag. (B) Bar graph indicates the frequency of Db/CN54gag tetramer+ CD8+ cells 
(mean ± SEM) enumerated in the blood and isolated genital tract tissue of naïve and 
rAdHu5-CN54gag MA immunized mice after 365 days. (C) Representative dot plots of 
Db/CN54gag tetramer+ CD8+ T cells assessed from blood (upper panels) and isolated 
genital tract tissue (lower panels) from mice enumerated in (B). (D) Representative 
contour plots showing the expression of KLRG1 and CD62L or CD103 and CD69 
among Db/CN54gag tetramer+ CD8+ T cells isolated from blood (upper panels) or 
genital tract tissue (lower panels) of mice immunized with rAdHu5-CN54gag MA 365 
days prior to analysis. (E) Representative histograms indicating the frequency of 
CD127, CXCR3 or CD49a expressing Db/CN54gag tetramer+ CD8+ T cells (red 
histograms) isolated from blood (upper panels) or genital tract (lower panels) of mice 
immunized with rAdHu5-CN54gag MA 365 days prior to analysis. Grey histograms 
represent staining with isotype control. Data are from one experiment (n=4/group).  
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3.6. rAd5Hu-CN54gag MA immunisation generates long-lived tissue resident memory 
CD8+ T cells within respiratory tract 
To extend our observations to another peripheral tissue, we investigated whether MA skin 
immunisation led to the accumulation of long-lived Ag-specific CD8+ T cells in the respiratory 
tract (Fig. 7A).  At one-year post immunisation, both, BAL and lung tissue collected from 
immunized mice revealed a substantial population of Db/CN54gag tetramer+ CD8+ T cells 
(Fig. 7B, 7C and 7D). Such tetramer tracked CD8+ T cells recovered from the lung were 
simultaneously negative for KLRG-1 and CD62L (Fig. 7E) consistent with a memory 
phenotype and revealed a tissue resident phenotype, defined by co-expression of CD103 
and CD69 that was imprinted by vaccination and consistent with their confinement to the 
lung parenchyma (Fig. 7E). Strikingly, Db/CN54gag tetramer
+
 CD8
+
 T cells from the lung 
demonstrated variable expression of CXCR3, CD49a and CD127 (Fig. 7F) and emphasised 
MA vaccination induced complementary CD69
+CD103+CXCR3hi and CD69+CD103+CXCR3lo 
populations detected in the lung. Most probably the respective CD8+ T cell subsets reflect 
their programmed differentiation and localization in separate anatomic sites in the lung [24]. 
Collectively, these results indicate that skin immunisation with an Ad viral vectored vaccine 
generated antigen-specific CD8+ T cell immunity engendering long-lasting memory 
responses not only in the systemic compartment, but more importantly, in the peripheral 
mucosal tissues, where heterogeneous CD8+ T cell subsets in a layered response could 
play a crucial role to control pathogenic infection. 
 
Fig. 7:  rAdHu5-CN54gag MA immunisation generates long-lived, antigen-specific, 
tissue resident memory CD8
+
 T cells within the respiratory tract. (A) Schematic of the 
experimental design to assess Db/CN54gag tetramer+ CD8+ T-cells in BAL and lung 
parenchyma 365 days after MA immunisation with rAdHu5-CN54gag. (B) Flow 
cytometric analysis showing Db/CN54gag tetramer+ cells among CD45+CD8+ T cells 
isolated from BAL of naïve or MA immunized mice. (C) Bar graph indicates the 
frequency of Db/CN54gag tetramer+ CD8+ cells (mean ± SEM) enumerated in lung 
tissue of naïve and rAdHu5-CN54 gag MA immunized mice after 365 days. (D) Lung 
tissues isolated from naïve mice or rAdHu5-CN54gag MA immunized mice were 
assessed after 365 days for infiltration of Db/CN54gag tetramer+ CD8+ T cells by flow 
cytometry. (E)  Representative contour plots showing the expression of KLRG1 and 
CD62L (left) or CD103 and CD69 (right) among Db/CN54gag tetramer+ CD8+ T cells 
isolated from lung tissues of mice immunized with rAdHu5-CN54gag MA 365 days 
prior to analyses. (F) Representative histograms indicating the frequency of CD127, 
CXCR3 or CD49a expressing Db/CN54gag tetramer+ CD8+ T cells (red histograms) 
isolated from lungs of mice immunized with rAdHu5-CN54gag MA 365 days prior to 
analysis. Grey histograms represent staining with isotype controls. Data are from one 
experiment (n=4/group).  
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3.7.  Vaccine elicited CD8+ T cells retain functionality one-year post MA vaccination 
 
Although the generation and maintenance of immunological memory is a prerequisite of a 
vaccine, functional competence is essential during a recall response to immunological 
challenge. To that end, one year post MA vaccination, splenic CD8+ T were sensitized in 
vitro with cognate HIV-1 CN54 gag308–318 peptide for 4 days to expand cells (Fig. 8A) and the 
ability of responders to produce IFNγ, an antiviral cytokine and also mediators of cytotoxic 
effector function (Granzyme B) was assayed by intracellular cytokine staining and flow 
cytometry after stimulation with PMA and Ionomycin (Fig. 8B). Background levels of IFNγ 
and Granzyme B were determined in the absence of peptide stimulation (peptide control). 
Antigen specific CD8+ T cells sensitized with HIV-1 CN54 gag308-318 peptide derived from MA 
vaccinated mice generated high frequency monofunctional IFNγ+ Granzyme B− cells 
compared to un-stimulated controls (p< 0.05). Similarly, high frequency polyfunctional, 
IFNγ+ Granzyme B+ cells were detected following in vitro expansion when compared with 
peptide-unstimulated controls (p<0.05) (Fig. 8B and 8C). These data establish that MA 
vaccinated mice produced long-lived antigen specific cells that retain T-cell effector 
functionality. 
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Fig. 8: Antigen–specific CD8+ T cells retain functionality one-year post MA 
vaccination. (A) Schematic of the experimental design; single cells from the spleen of 
MA immunized mice 365 days post-vaccination were sensitized in vitro with an HIV-1 
CN54 gag308-318 peptide for 4 days or left untreated prior to intracellular cytokine 
staining performed for IFNγ and Granzyme B in the presence of PMA and Ionomycin. 
(B) gated CD8
+
, MHCII
-
, CD4
-
 cells (left) were further assessed for poly-functionality by 
flow cytometry. Biaxial plots demonstrate simultaneous detection of IFNγ and 
Granzyme B (right). Isotype control staining is also shown (far right). (C) Bar graph 
indicates the frequency of Db/CN54gag tetramer+ CD8+ cells (mean ± SEM) 
enumerated from data shown in (B).  Data are from one experiment (n=4/group).  
 
Discussion 
 
The success of live viral vectored vaccines in eliciting potent cellular immune responses lies 
in their capacity to efficiently infect (or transduce) antigen presenting cells, directly [25] or 
indirectly[26, 27] and prime antigen-specific CD8+ T cells without the need of an adjuvant 
[28, 29]. The challenge has been to retain the immunogenicity of these live vaccines when 
lyophilized or dried in a MA platform (to eliminate cold chain storage) and at the same time 
induce a multi-layered memory CD8+ T cell response providing immune surveillance at each 
immune barrier; mucosal, central lymphoid and vascular against invading pathogens. Here 
we report the first evidence that fabrication of a dried MA formulated from a dissolvable 
polymer containing a live recombinant AdHu5 vector when delivered to skin has the capacity 
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to elicit long-lived antigen–specific CD8+ T cells at the mucosal barrier. Specifically, we 
reveal that CD8+ TRM cells programmed with antiviral effector function were induced and 
retained both in the genital and respiratory tracts for at least one year following vaccination 
with an exemplar (rAdHu5 HIV-1 gag) vaccine released from the matrix of a rapidly 
dissolvable MA.  
Prior studies have successfully demonstrated the ability of dried MA virus vectored vaccines 
to instruct memory CD8
+
 T cell responses in secondary lymphoid tissues [14-16, 30] and 
also programme CD8+ TEM cells that patrol non-lymphoid tissues [16]. Indeed it is widely 
accepted that T cells activated at any site, whether through local or systemic priming, can 
gain the capacity to circulate through almost all tissues in the body [31, 32] and be recruited 
to sites of virus infection.  However, for viruses that enter via the epithelial surfaces, such as 
HIV, herpes simplex, influenza virus and Zika virus, the deployment of TRM cells that 
permanently reside within the epithelia following priming may be critical for rapid initial virus 
control, before other memory T cell populations are recruited to prevent systemic virus 
spread [33, 34].  In that regard, our data extend the known capabilities of the MA delivery 
platform by demonstrating that MA vaccination through the skin promotes priming and 
retention of TRM cells in the female genital tract and in the lung.  
 
Although it has been reported that local antigen is necessary to drive the generation of TRM 
cells in mucosal tissues [33, 35, 36] previous studies nonetheless reported that systemic 
immunization with non-replicating viral vectors induced CD8+ T cell responses in the female 
genital tract [37-39]. However, unlike those reports where vaccine delivery required 
traditional needle-based immunization; our data provide evidence that MA immunization 
engenders retention of antigen-specific CD8+ TRM cells without the necessity for vaccine 
reconstitution, hypodermic needle delivery or cold chain vaccine vector storage.  Of caution, 
prior studies [37-39] left open the possibility that memory CD8+ T cells reported as isolated 
from the genital tract following systemic immunization may have been derived from the 
vasculature during tissue disaggregation. To exclude that possibility, we comprehensively 
phenotyped antigen-specific CD8+ T cells tracked by tetramer in the genital tract for 
peripheral tissue retention markers that are signatures of CD8+ TRM cells. At 150 and 365 
days after MA immunization, tetramer-specific CD8+ T cells in the genital tract uniformly 
E integrin binding E-cadherin, highly expressed on epithelia 
[40] and also expressed CD69, an antagonist to sphingosine 1-phosphate receptor 1 
(S1PR1) that regulates egress from tissues [41]. These data strongly suggest rAdHu5 
vectored MA immunization promotes the differentiation and retention of a subpopulation of 
primed CD8+ T cells in female genital mucosa. Consistent with their barrier tissue 
localisation, a high frequency of CD8+ TRM cells induced by MA immunization in the genital 
tract and lungs co-expressed CD49a, a biomarker that defines TRM cells poised with 
cytotoxic potential [42, 43]. The fact that tetramer+CD103+CD69+CD8+ T cells were retained 
for up to one year in mucosal tissues in the absence of any booster vaccination may suggest 
that once this memory population is programmed by MA vaccination, that local signals 
promote their long term survival.  
 
Cutaneous MA immunization also elicited high frequency antigen-specific 
CD103
+
CD69
+
CD8
+
 TRM cells that were localized in the lung. Most unexpectedly, two distinct 
populations of CD103+CD69+CD8+ TRM cells, identified as CXCR3
LO and CXCR3HIwere 
retained in the lung one-year post MA immunization, which was not apparent among the 
CD8+ TRM cells retained in genital tract tissue that were uniformly CXCR3
HICD49aHi. The 
functional consequences of distinct subsets of lung resident memory CD8+ T cells induced 
by MA immunization remains to be clarified. In this regard, MA induced CXCR3LO CD8+ TRM 
cells might reside in a distinct niche within the lung interstitium as reported after intranasal 
immunization [35] and a CXCR3HI CD8+ TRM subset within the lung airway [35]. This remains 
to be clarified, though for now however, the data offer strong support for the idea that MA 
immunization elicits overlapping CD8+ TRM populations that patrol the lungs possibly for rapid 
and delayed mobilization [35]. 
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Understanding the long-term capacity of MA elicited memory CD8+ T cells to respond to 
recall antigen is pivotal to enable further development and future clinical deployment of this 
vaccination platform. To that end, memory CD8+ T cells generated one year post MA 
vaccination maintained Granzyme B expression mediating their ex vivo cytotoxicity, in a 
similar manner to antigen-specific effector CD8+ T cells [44, 45]. Rapid delivery of cytotoxic 
molecules represents only one potential mechanism to eliminate anamnestic infections. 
Here, we also show that a large proportion of MA elicited HIV-1 gag308-319 specific memory 
CD8+ T cells also released IFN as an antiviral effector, or co-expressed both IFN- and 
Granzyme B in a response to peptide re-stimulation, confirming their desirable T-cell effector 
poly-functionality. Our study also demonstrated a durable ability of MA induced CD8+ T cells 
to respond to secondary antigen challenge in the vagina with an apparent 5 to 6-fold 
increase in the frequency of Db/tetramer+ CD8+ T cells in the genital tract tissues. This 
expansion, likely involved recruitment of KLRG-1+ short term effectors from the draining 
lymph nodes to the genital tract with enhanced kinetics following antigen challenge at that 
site, as at a minimum, one third of Db/tetramer
+
 CD8
+
 T cells in the genital tract of antigen 
challenged mice displayed an effector phenotype (KLRG-1+ CD62L-). In that regard, 
enrichment of effector CD8
+
 T cells following challenge is consistent with earlier reports of T 
cell mobilization from the iliac lymph nodes to the vagina after vaginal antigen/virus 
challenge [38, 46].  
 
Our study lends strong support for the premise that MA vaccination of an accessible tissue, 
the skin, enables rapid vaccine dissolution and elicits a long-lived KLRG-1- CD62L- CD103+ 
CD69+CXCR3+ TRM memory population expressing CD49a, programmed for rapid antiviral 
deployment in the genital and respiratory tract that is complemented by lymphoid tissue 
based CD8+ TCM and patrolling CD8
+TEM cells that in aggregate can provide a multi-layered 
immune response to pathogen challenge.  
 
Conclusions 
 
Overall, this study shows that the dissolving MA delivery platform offers an attractive 
approach to administer rAdHu5 virus vectored vaccines to generate long-lived antigen 
specific CD8+ T cells that reside within the barrier surfaces, retaining their T-effector poly-
functionality and demonstrating durable ability to respond to secondary antigen challenge. 
This property of the MA-mediated vaccine delivery platform, to programme the expression of 
peripheral tissue homing and retention molecules on the responding HIV-specific CD8+ T 
cells, has a potential to substantially increase the protective efficacy at the entry point of this 
and other pathogens. This attribute, combined with the significant logistical advantages 
offered by microneedle technology (cold chain independence, increased safety due to 
elimination of hazardous sharps, ease of administration and likely increased patient 
compliance), bode well for advancing deployment of the MA vaccine technology in the clinic, 
not only restricted to the context of infectious diseases, but also in other therapeutic 
applications. Going forward, transition to the clinic will require a GMP manufacturing process 
and GMP packaging to protect the MAs in storage and distribution. Additionally, an 
applicator may prove beneficial for MA delivery by trained healthcare workers in the first 
instance. Nonetheless, incorporation of a pressure sensing film may enable self-application 
in the future by indicating the appropriate pressure to apply for effective MA delivery. 
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